Chloe N. Thomas
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Chloe N. Thomas has a total of 75 co-authors. Here are the top co-authors by number of shared publications:
- Lisa J. Hill
Department of Biomedical Sciences, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK
6 shared publications - Zubair Ahmed
Department of Inflammation and Ageing, School of Infection, Inflammation and Immunology, College of Medicine and Health, University of Birmingham, Birmingham, UK
6 shared publications Ann Logan
Neuroscience and Ophthalmology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom
3 shared publicationsMartin Berry
Neuroscience and Ophthalmology Research Group, Institute of Inflammation and Ageing, University of Birmingham, Birmingham, United Kingdom
3 shared publications- Richard James Blanch
Ophthalmology Department, University Hospitals Birmingham NHS Foundation Trust, Birmingham, UK
3 shared publications - Adam M. Thompson
Neuroscience and Ophthalmology, Institute of Inflammation and Ageing, University of Birmingham, Birmingham B15 2TT, UK
2 shared publications
Latest Publications
- Open Access
- 24 August 2026
- Published by Wiley in Experimental Physiology
Thermoregulatory and plasma neurobiomarker responses to heat tolerance assessment in exertional heat illness and matched controls
Exercise in the heat and elevated tissue temperature are associated with neuronal stress and changes in blood–brain barrier (BBB) function. More severe thermal insult may manifest as exertional heat illness (EHI) and complication by central nervous system (CNS) dysfunction may persist post‐EHI. We investigated neurobiomarkers associated with neuronal injury (brain‐derived tau, BD‐tau; neurofilament light, NfL; ubiquitin carboxyl‐terminal hydrolase isozyme L1, UCH‐L1) and BBB function (glial fibrillary acid protein, GFAP) in the peripheral blood of 34 recent (∼4 months) EHI patients and 30 Control individuals without prior EHI history, matched for variables influencing thermoregulation. Participants completed an exercise heat tolerance assessment (HTA), with neurobiomarkers measured pre‐ and post‐HTA. An equal number of participants ( n = 6) in both EHI and Control groups showed thermoregulatory responses consistent with thermal intolerance. Pooled changes in BD‐tau, GFAP and UCH‐L1 showed moderate to large effect sizes (Cohen's d = 1.2, −1.3 and 0.75, respectively), including novel elevation in BD‐tau (median [interquartile range] 4.84 [4.10, 5.51] vs. 6.89 [5.69, 7.85] pg mL −1 ), whereas impact of HTA on NfL was negligible (Cohen's d = 0.03). No differences were evident in neurobiomarker response between EHI and Controls (time × group interaction P = 0.244), and no consistent associations between body core temperature and neurobiomarker concentrations were demonstrated. In conclusion, neurobiomarker responses to HTA were similar between EHI cases and Controls, indicating an absence of ongoing CNS injury in this patient cohort. However, variability in neurobiomarkers with HTA queries the general applicability of these biochemical surrogates in the management of brain insult associated with prior exercise and thermal stress.
- 24 August 2026
- Published by Wiley in Experimental Physiology
Open AccessThermoregulatory and plasma neurobiomarker responses to heat tolerance assessment in exertional heat illness and matched controls
Exercise in the heat and elevated tissue temperature are associated with neuronal stress and changes in blood–brain barrier (BBB) function. More severe thermal insult may manifest as exertional heat illness (EHI) and complication by central nervous system (CNS) dysfunction may persist post‐EHI. We investigated neurobiomarkers associated with neuronal injury (brain‐derived tau, BD‐tau; neurofilament light, NfL; ubiquitin carboxyl‐terminal hydrolase isozyme L1, UCH‐L1) and BBB function (glial fibrillary acid protein, GFAP) in the peripheral blood of 34 recent (∼4 months) EHI patients and 30 Control individuals without prior EHI history, matched for variables influencing thermoregulation. Participants completed an exercise heat tolerance assessment (HTA), with neurobiomarkers measured pre‐ and post‐HTA. An equal number of participants ( n = 6) in both EHI and Control groups showed thermoregulatory responses consistent with thermal intolerance. Pooled changes in BD‐tau, GFAP and UCH‐L1 showed moderate to large effect sizes (Cohen's d = 1.2, −1.3 and 0.75, respectively), including novel elevation in BD‐tau (median [interquartile range] 4.84 [4.10, 5.51] vs. 6.89 [5.69, 7.85] pg mL −1 ), whereas impact of HTA on NfL was negligible (Cohen's d = 0.03). No differences were evident in neurobiomarker response between EHI and Controls (time × group interaction P = 0.244), and no consistent associations between body core temperature and neurobiomarker concentrations were demonstrated. In conclusion, neurobiomarker responses to HTA were similar between EHI cases and Controls, indicating an absence of ongoing CNS injury in this patient cohort. However, variability in neurobiomarkers with HTA queries the general applicability of these biochemical surrogates in the management of brain insult associated with prior exercise and thermal stress.
- Open Access
- 14 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (1) , e218162
Identifying MicroRNA Biomarkers in Idiopathic Intracranial Hypertension
Idiopathic intracranial hypertension (IIH) is characterized by raised intracranial pressure (ICP). It predominantly affects women with obesity and can cause disabling headaches and permanent visual loss. IIH is misdiagnosed in up to 40% of cases. Diagnosis and monitoring often rely on frequent invasive lumbar puncture. This pilot study aimed to identify serum microRNA (miRNA) markers associated with a diagnosis of IIH and disease activity and to assess their relevance in the CNS through identification in CSF. Serum and CSF samples from participants in the IIH-Weight Trial (a randomized controlled trial comparing the effectiveness of bariatric surgery with that of a community weight management intervention in lowering ICP, recruited 2014-2017) were analyzed at baseline (active disease) and 12 months (participants in remission with no papilledema). Eligible participants were adult women with active IIH (those without papilledema were excluded). Disease activity was assessed by quantifying the degree of papilledema using Spectralis spectral-domain optical coherence tomography. A panel of 40 candidate miRNAs was assessed. Comparator groups included participants with obesity or migraine. Analyses used Student t tests and one-way ANOVA followed by Tukey multiple comparisons test. Differentially expressed miRNAs were evaluated in relation to clinical disease activity and metabolic profiles, using linear regression analysis. Five of 40 serum miRNAs showed significantly lower expression in active IIH (n = 9; 100% female, mean 30.25 ± 4.75 years) compared with IIH in remission. Serum hsa-miR-16-5p had the highest diagnostic performance for active IIH (area under the curve 0.951). Serum hsa-miR-16-5p (p < 0.0001; CI -7.286 to -2.503) and hsa-miR-7-5p (p = 0.0032; CI -7.240 to -1.372) were significantly lower in active IIH compared with obesity controls (n = 9; 100% female, mean 38.22 ± 7.99 years). Serum hsa-miR-7a-5p were significantly higher in active IIH compared with migraine (n = 12; 100% female, mean 44.67 ± 8.88 years). Only hsa-miR-16-5p differentiated active IIH from both participants with migraine and obesity. hsa-miR-16-5p also differentiated active IIH from IIH remission in CSF (p = 0.0354; CI -3.062 to -0.1282). Serum and CSF hsa-miR-16-5p correlated significantly with ICP (serum p < 0.0001; CI -0.1660 to -0.0732; CSF p = 0.046; CI 0.0018-0.1841), papilledema (serum p = 0.0236; CI -0.01548 to -0.0001; CSF p = 0.0241; CI 0.002-0.033). hsa-miR-16-5p was associated with metabolites involved in fatty acid metabolism and lipid biosynthesis. Serum hsa-miR-16-5p emerged as a candidate biomarker associated with active IIH. It differentiated active disease from remission, migraine, and obesity. It correlated with clinical and metabolic markers of disease activity. These findings warrant validation in larger studies to assess its potential as a minimally invasive biomarker for IIH diagnosis and monitoring. This study provides Class III evidence that serum microRNA markers may potentially distinguish active idiopathic intracranial hypertension from remission and controls in adult women.
- 14 July 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (1) , e218162
Open AccessIdentifying MicroRNA Biomarkers in Idiopathic Intracranial Hypertension
Idiopathic intracranial hypertension (IIH) is characterized by raised intracranial pressure (ICP). It predominantly affects women with obesity and can cause disabling headaches and permanent visual loss. IIH is misdiagnosed in up to 40% of cases. Diagnosis and monitoring often rely on frequent invasive lumbar puncture. This pilot study aimed to identify serum microRNA (miRNA) markers associated with a diagnosis of IIH and disease activity and to assess their relevance in the CNS through identification in CSF. Serum and CSF samples from participants in the IIH-Weight Trial (a randomized controlled trial comparing the effectiveness of bariatric surgery with that of a community weight management intervention in lowering ICP, recruited 2014-2017) were analyzed at baseline (active disease) and 12 months (participants in remission with no papilledema). Eligible participants were adult women with active IIH (those without papilledema were excluded). Disease activity was assessed by quantifying the degree of papilledema using Spectralis spectral-domain optical coherence tomography. A panel of 40 candidate miRNAs was assessed. Comparator groups included participants with obesity or migraine. Analyses used Student t tests and one-way ANOVA followed by Tukey multiple comparisons test. Differentially expressed miRNAs were evaluated in relation to clinical disease activity and metabolic profiles, using linear regression analysis. Five of 40 serum miRNAs showed significantly lower expression in active IIH (n = 9; 100% female, mean 30.25 ± 4.75 years) compared with IIH in remission. Serum hsa-miR-16-5p had the highest diagnostic performance for active IIH (area under the curve 0.951). Serum hsa-miR-16-5p (p < 0.0001; CI -7.286 to -2.503) and hsa-miR-7-5p (p = 0.0032; CI -7.240 to -1.372) were significantly lower in active IIH compared with obesity controls (n = 9; 100% female, mean 38.22 ± 7.99 years). Serum hsa-miR-7a-5p were significantly higher in active IIH compared with migraine (n = 12; 100% female, mean 44.67 ± 8.88 years). Only hsa-miR-16-5p differentiated active IIH from both participants with migraine and obesity. hsa-miR-16-5p also differentiated active IIH from IIH remission in CSF (p = 0.0354; CI -3.062 to -0.1282). Serum and CSF hsa-miR-16-5p correlated significantly with ICP (serum p < 0.0001; CI -0.1660 to -0.0732; CSF p = 0.046; CI 0.0018-0.1841), papilledema (serum p = 0.0236; CI -0.01548 to -0.0001; CSF p = 0.0241; CI 0.002-0.033). hsa-miR-16-5p was associated with metabolites involved in fatty acid metabolism and lipid biosynthesis. Serum hsa-miR-16-5p emerged as a candidate biomarker associated with active IIH. It differentiated active disease from remission, migraine, and obesity. It correlated with clinical and metabolic markers of disease activity. These findings warrant validation in larger studies to assess its potential as a minimally invasive biomarker for IIH diagnosis and monitoring. This study provides Class III evidence that serum microRNA markers may potentially distinguish active idiopathic intracranial hypertension from remission and controls in adult women.
- Open Access
- 18 December 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (1)
Biofluid-based predictors of post-concussion symptoms: a narrative review of mild traumatic brain injury biomarkers
Mild traumatic brain injury can disrupt brain function and is associated with high morbidity and healthcare utilization. While many individuals recover from mild traumatic brain injury, a significant proportion experience long-term sequelae, collectively known as post-concussion syndrome. Symptoms of post-concussion syndrome include headache, dizziness, insomnia, cognitive processing difficulties and mental health disturbances. The disease burden is augmented by the current lack of objective measures to accurately predict long-term symptoms and deficits, providing an opportunity to utilize biomarkers in biofluids. A large proportion of available diagnostic clinical tools are subjective symptom scores. This review aims to explore current fluid biomarkers, grouped by clinical symptoms. With the available literature, we have discovered a wide range of fluid biomarkers that have been investigated for predicting post-traumatic headache, including neuropeptides; sleep disturbances, such as cortisol and melatonin; vestibular disturbances, including interleukin-6 and neurone-specific enolase; and vomiting, such as S100B. Along with physical symptoms, biomarkers investigated for predicting cognitive disturbances include inflammatory markers, S100B, neurofilament light chain, tau, microRNA and hormones. Biomarkers to predict mental health disturbances may include brain-derived neurotrophic factor, tau and cortisol. By utilizing such biomarkers, there is capacity to adopt a personalized medicine approach to facilitate early interventions for those most in need while also identifying individuals with a favourable prognosis who can safely return to their normal activities.
- 18 December 2025
- Published by Oxford University Press (OUP) in Brain Communications
- Vol. 8 (1)
Open AccessBiofluid-based predictors of post-concussion symptoms: a narrative review of mild traumatic brain injury biomarkers
Mild traumatic brain injury can disrupt brain function and is associated with high morbidity and healthcare utilization. While many individuals recover from mild traumatic brain injury, a significant proportion experience long-term sequelae, collectively known as post-concussion syndrome. Symptoms of post-concussion syndrome include headache, dizziness, insomnia, cognitive processing difficulties and mental health disturbances. The disease burden is augmented by the current lack of objective measures to accurately predict long-term symptoms and deficits, providing an opportunity to utilize biomarkers in biofluids. A large proportion of available diagnostic clinical tools are subjective symptom scores. This review aims to explore current fluid biomarkers, grouped by clinical symptoms. With the available literature, we have discovered a wide range of fluid biomarkers that have been investigated for predicting post-traumatic headache, including neuropeptides; sleep disturbances, such as cortisol and melatonin; vestibular disturbances, including interleukin-6 and neurone-specific enolase; and vomiting, such as S100B. Along with physical symptoms, biomarkers investigated for predicting cognitive disturbances include inflammatory markers, S100B, neurofilament light chain, tau, microRNA and hormones. Biomarkers to predict mental health disturbances may include brain-derived neurotrophic factor, tau and cortisol. By utilizing such biomarkers, there is capacity to adopt a personalized medicine approach to facilitate early interventions for those most in need while also identifying individuals with a favourable prognosis who can safely return to their normal activities.
- Open Access
- 1 August 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 66 (11) , 45
Mathematical Models of Topically and Intravitreally Applied Ranibizumab
Wet age-related macular degeneration (AMD) causes vision loss when vascular endothelial growth factor (VEGF) stimulates blood vessel growth into the light-sensitive retina. Anti-VEGF treatments such as ranibizumab are currently administered to treat wet AMD via intravitreal injections, which are unpleasant, expensive, and risk complications. We explored the efficacy of topically administered ranibizumab, with cell-penetrating peptides (CPPs). Ex vivo pig eyes were divided into three groups and treated with (1) topical or (2) intravitreal ranibizumab and CPP, or (3) intravitreal ranibizumab. ELISAs measured ranibizumab and VEGF concentrations in the aqueous and vitreous at 20 min, 40 min, 1 h, and 3.5 h (n = 3, per group). An ordinary differential equation model was formulated to describe the evolving concentrations of ranibizumab, VEGF, and their compounds in the tear, aqueous, and vitreal compartments. Experimental-Topical: aqueous ranibizumab levels increased significantly, coincident with a significant drop in aqueous VEGF. Vitreal ranibizumab increased significantly, while vitreal VEGF remained constant. Intravitreal (with and without CPP): vitreal ranibizumab reached high concentrations, coincident with a significant drop in vitreal VEGF. Mathematical-topical treatment may provide sustained, moderate suppression of vitreal VEGF levels, while intravitreal treatment provides strong suppression, which lessens between treatments. CPP allows topical ranibizumab to penetrate the cornea. Combined intravitreal/topical treatment presents a promising approach; topical treatment suppresses vitreal VEGF levels between injections and thereby potentially reduces the frequency of injections. Treatment efficacy would be enhanced if ranibizumab's rate of binding to VEGF or tear residence time could be increased.
- 1 August 2025
- Published by Association for Research in Vision and Ophthalmology (ARVO) in Investigative Ophthalmology & Visual Science
- Vol. 66 (11) , 45
Open AccessMathematical Models of Topically and Intravitreally Applied Ranibizumab
Wet age-related macular degeneration (AMD) causes vision loss when vascular endothelial growth factor (VEGF) stimulates blood vessel growth into the light-sensitive retina. Anti-VEGF treatments such as ranibizumab are currently administered to treat wet AMD via intravitreal injections, which are unpleasant, expensive, and risk complications. We explored the efficacy of topically administered ranibizumab, with cell-penetrating peptides (CPPs). Ex vivo pig eyes were divided into three groups and treated with (1) topical or (2) intravitreal ranibizumab and CPP, or (3) intravitreal ranibizumab. ELISAs measured ranibizumab and VEGF concentrations in the aqueous and vitreous at 20 min, 40 min, 1 h, and 3.5 h (n = 3, per group). An ordinary differential equation model was formulated to describe the evolving concentrations of ranibizumab, VEGF, and their compounds in the tear, aqueous, and vitreal compartments. Experimental-Topical: aqueous ranibizumab levels increased significantly, coincident with a significant drop in aqueous VEGF. Vitreal ranibizumab increased significantly, while vitreal VEGF remained constant. Intravitreal (with and without CPP): vitreal ranibizumab reached high concentrations, coincident with a significant drop in vitreal VEGF. Mathematical-topical treatment may provide sustained, moderate suppression of vitreal VEGF levels, while intravitreal treatment provides strong suppression, which lessens between treatments. CPP allows topical ranibizumab to penetrate the cornea. Combined intravitreal/topical treatment presents a promising approach; topical treatment suppresses vitreal VEGF levels between injections and thereby potentially reduces the frequency of injections. Treatment efficacy would be enhanced if ranibizumab's rate of binding to VEGF or tear residence time could be increased.
- Open Access
- 13 August 2022
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 216, 114623
Triazole-derivatized near-infrared cyanine dyes enable local functional fluorescent imaging of ocular inflammation
- 13 August 2022
- Published by Elsevier in Biosensors and Bioelectronics
- Vol. 216, 114623
Open AccessTriazole-derivatized near-infrared cyanine dyes enable local functional fluorescent imaging of ocular inflammation
- Open Access
Addendum: Thomas et al. Retinal Ganglion Cells Die by Necroptotic Mechanisms in a Site-Specific Manner in a Rat Blunt Ocular Injury Model. Cells 2019, 8, 1517
The authors would like to make an addendum to their published paper
Open AccessAddendum: Thomas et al. Retinal Ganglion Cells Die by Necroptotic Mechanisms in a Site-Specific Manner in a Rat Blunt Ocular Injury Model. Cells 2019, 8, 1517
The authors would like to make an addendum to their published paper
- Open Access
- 26 March 2021
- Published by Wiley in British Journal of Pharmacology
- Vol. 179 (9) , 1908-1937
Emerging therapies and their delivery for treating age‐related macular degeneration
Age‐related macular degeneration (AMD) is the most common cause of blindness in the Western world and is characterised in its latter stages by retinal cell death and neovascularisation and earlier stages with the loss of parainflammatory homeostasis. Patients with neovascular AMD (nAMD) are treated with frequent intraocular injections of anti‐vascular endothelial growth factor (VEGF) therapies, which are not only unpopular with patients but carry risks of sight‐threatening complications. A minority of patients are unresponsive with no alternative treatment available, and some patients who respond initially eventually develop a tolerance to treatment. New therapeutics with improved delivery methods and sustainability of clinical effects are required, in particular for non‐neovascular AMD (90% of cases and no current approved treatments). There are age‐related and disease‐related changes that occur which can affect ocular drug delivery. Here, we review the latest emerging therapies for AMD, their delivery routes and implications for translating to clinical practice.LINKED ARTICLES: This article is part of a themed issue on Inflammation, Repair and Ageing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.9/issuetoc
- 26 March 2021
- Published by Wiley in British Journal of Pharmacology
- Vol. 179 (9) , 1908-1937
Open AccessEmerging therapies and their delivery for treating age‐related macular degeneration
Age‐related macular degeneration (AMD) is the most common cause of blindness in the Western world and is characterised in its latter stages by retinal cell death and neovascularisation and earlier stages with the loss of parainflammatory homeostasis. Patients with neovascular AMD (nAMD) are treated with frequent intraocular injections of anti‐vascular endothelial growth factor (VEGF) therapies, which are not only unpopular with patients but carry risks of sight‐threatening complications. A minority of patients are unresponsive with no alternative treatment available, and some patients who respond initially eventually develop a tolerance to treatment. New therapeutics with improved delivery methods and sustainability of clinical effects are required, in particular for non‐neovascular AMD (90% of cases and no current approved treatments). There are age‐related and disease‐related changes that occur which can affect ocular drug delivery. Here, we review the latest emerging therapies for AMD, their delivery routes and implications for translating to clinical practice.LINKED ARTICLES: This article is part of a themed issue on Inflammation, Repair and Ageing. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v179.9/issuetoc
- 1 August 2020
- Published by Elsevier in Experimental Eye Research
- Vol. 197, 108102
Assessment of necroptosis in the retina in a repeated primary ocular blast injury mouse model
- 1 August 2020
- Published by Elsevier in Experimental Eye Research
- Vol. 197, 108102
Assessment of necroptosis in the retina in a repeated primary ocular blast injury mouse model
- Open Access
Retinal Ganglion Cells Die by Necroptotic Mechanisms in a Site-Specific Manner in a Rat Blunt Ocular Injury Model
Closed-globe injury can cause visual loss in military and civilian populations, with retinal cell death, including retinal ganglion cell (RGC) degeneration, leading to irreversible blindness. RGC and optic nerve (ON) degeneration after eye or head injury is termed traumatic optic neuropathy (TON). There are currently no treatments for RGC loss, therefore novel therapeutics to prevent RGC death or promote axonal regeneration are a priority. We investigated necroptotic signaling mechanisms in a rat blunt ocular injury model. After bilateral blunt trauma, protein expression and retinal localization of necroptosis pathway members (receptor interacting protein kinase 1, RIPK1; receptor interacting protein kinase 3, RIPK3; and mixed lineage kinase domain like pseudokinase, MLKL) were assessed by Western blot and immunohistochemistry (IHC), and potent necroptosis inhibitor Necrostatin-1s (Nec-1s) was delivered by intravitreal injection to one eye and vehicle to the contralateral eye. RGC and photoreceptor survival were assessed by cell counting and outer nuclear layer (ONL) thickness measurements on histology. The neuroprotective effects of Nec-1s were assessed in primary retinal culture by βIII-tubulin+ RGC cell counts. MLKL protein expression were upregulated at 48 h after injury and MLKL immunolocalised to retinal binding protein with multiple splice (RBPMS)+ RGC, inner nuclear cells and ONL cells, specifically at the retinal injury site. RIPK3 expression did not increase but RIPK3 co-immunolocalised with RBPMS+ RGC in intact and injured retinae. In vitro, a Nec-1s concentration of 0.01 pg/µL was RGC neuroprotective. In the blunt ocular injury rat model, Nec-1s prevented RGC death at the center of the impact site but did not protect against ONL thinning or provide functional restitution. RGC degeneration in our blunt ocular injury model is site-specific, with necroptosis driving death at the center of the focal impact site.
Open AccessRetinal Ganglion Cells Die by Necroptotic Mechanisms in a Site-Specific Manner in a Rat Blunt Ocular Injury Model
Closed-globe injury can cause visual loss in military and civilian populations, with retinal cell death, including retinal ganglion cell (RGC) degeneration, leading to irreversible blindness. RGC and optic nerve (ON) degeneration after eye or head injury is termed traumatic optic neuropathy (TON). There are currently no treatments for RGC loss, therefore novel therapeutics to prevent RGC death or promote axonal regeneration are a priority. We investigated necroptotic signaling mechanisms in a rat blunt ocular injury model. After bilateral blunt trauma, protein expression and retinal localization of necroptosis pathway members (receptor interacting protein kinase 1, RIPK1; receptor interacting protein kinase 3, RIPK3; and mixed lineage kinase domain like pseudokinase, MLKL) were assessed by Western blot and immunohistochemistry (IHC), and potent necroptosis inhibitor Necrostatin-1s (Nec-1s) was delivered by intravitreal injection to one eye and vehicle to the contralateral eye. RGC and photoreceptor survival were assessed by cell counting and outer nuclear layer (ONL) thickness measurements on histology. The neuroprotective effects of Nec-1s were assessed in primary retinal culture by βIII-tubulin+ RGC cell counts. MLKL protein expression were upregulated at 48 h after injury and MLKL immunolocalised to retinal binding protein with multiple splice (RBPMS)+ RGC, inner nuclear cells and ONL cells, specifically at the retinal injury site. RIPK3 expression did not increase but RIPK3 co-immunolocalised with RBPMS+ RGC in intact and injured retinae. In vitro, a Nec-1s concentration of 0.01 pg/µL was RGC neuroprotective. In the blunt ocular injury rat model, Nec-1s prevented RGC death at the center of the impact site but did not protect against ONL thinning or provide functional restitution. RGC degeneration in our blunt ocular injury model is site-specific, with necroptosis driving death at the center of the focal impact site.
- Open Access
- 29 October 2018
- Vol. 24, 712-726
TGF-β-induced IOP elevations are mediated by RhoA in the early but not the late fibrotic phase of open angle glaucoma
Purpose: Elevations in intraocular pressure (TOP) are associated with the development of glaucoma and loss of sight. High transforming growth factor-beta (TGF-beta) 1 levels in the eye's anterior chamber can lead to dysfunctional contractions through RhoA signaling in trabecular meshwork (TM) cells and IOP spikes. Sustained high TGF-beta levels leads to TM fibrosis and sustained increases in IOP. We investigated whether inhibiting RhoA, using a siRNA-mediated RhoA (siRhoA), controls IOP by altering TM expression of fibrosis and contractility-related proteins in a rodent model of glaucoma. Methods: TGF-beta was injected intracamerally twice a week into adult Sprague Dawley rats, and IOP was recorded with tonometry. Animals were euthanized on day 7 and 35 with TM expression of fibrosis and contractility-related proteins, as well as survival of retinal ganglion cells (RGCs) assessed with immunohistochemistry. siRNA against RhoA or enhanced green fluorescent protein (EGFP) was also injected intracamerally into select animals. Successful RhoA knockdown was determined with quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry, and the effects of the knockdown on the parameters above analyzed. Results: TGF-beta caused increased TM contractile proteins and IOP spikes by day 7, sustained increases in IOP from day 15, and TM fibrosis at day 35. siRhoA abolished the transient 7 day IOP rise but not the later sustained IOP increase (due to fibrosis). At 35 days, TGF-beta-related RGC loss was not prevented with siRhoA treatment. Conclusions: We conclude that RhoA signaling mediates the early IOP rise induced by TM cellular changes associated with contractility but not the sustained IOP elevation caused by TM fibrosis. Thus, RhoA therapies offer a clinically relevant opportunity for IOP management, likely through the modulation of TM contractility, but appear to be ineffective in the amelioration of fibrosis.
- 29 October 2018
- Vol. 24, 712-726
Open AccessTGF-β-induced IOP elevations are mediated by RhoA in the early but not the late fibrotic phase of open angle glaucoma
Purpose: Elevations in intraocular pressure (TOP) are associated with the development of glaucoma and loss of sight. High transforming growth factor-beta (TGF-beta) 1 levels in the eye's anterior chamber can lead to dysfunctional contractions through RhoA signaling in trabecular meshwork (TM) cells and IOP spikes. Sustained high TGF-beta levels leads to TM fibrosis and sustained increases in IOP. We investigated whether inhibiting RhoA, using a siRNA-mediated RhoA (siRhoA), controls IOP by altering TM expression of fibrosis and contractility-related proteins in a rodent model of glaucoma. Methods: TGF-beta was injected intracamerally twice a week into adult Sprague Dawley rats, and IOP was recorded with tonometry. Animals were euthanized on day 7 and 35 with TM expression of fibrosis and contractility-related proteins, as well as survival of retinal ganglion cells (RGCs) assessed with immunohistochemistry. siRNA against RhoA or enhanced green fluorescent protein (EGFP) was also injected intracamerally into select animals. Successful RhoA knockdown was determined with quantitative reverse transcription polymerase chain reaction (RT-PCR) and immunohistochemistry, and the effects of the knockdown on the parameters above analyzed. Results: TGF-beta caused increased TM contractile proteins and IOP spikes by day 7, sustained increases in IOP from day 15, and TM fibrosis at day 35. siRhoA abolished the transient 7 day IOP rise but not the later sustained IOP increase (due to fibrosis). At 35 days, TGF-beta-related RGC loss was not prevented with siRhoA treatment. Conclusions: We conclude that RhoA signaling mediates the early IOP rise induced by TM cellular changes associated with contractility but not the sustained IOP elevation caused by TM fibrosis. Thus, RhoA therapies offer a clinically relevant opportunity for IOP management, likely through the modulation of TM contractility, but appear to be ineffective in the amelioration of fibrosis.